Share This

A small genetic change can predict how people infected with hepatitis C react to treatment, paving the way to personalised therapy for this difficult to treat disease, the annual conference of the European Society of Human Genetics heard on June 13. Dr. Zoltan Kutalik, from the Department of Medical Genetics, University of Lausanne, Switzerland, told delegates that individuals with this change, in a gene encoding for the antiviral cytokine (cell-signalling molecule) interferon lamda, react less well to treatment. This knowledge could spare them the unpleasant side effects of a therapy which most likely would have little benefit for them, he says.

Related Articles

Hepatitis C is a serious liver disease, normally contracted through drug use, blood transfusion or sexual transmission. About 10% of all patients have no identifiable source of infection. The virus produces chronic infection in around 80% of infected individuals, and half of these do not respond to existing therapies. Current treatment involves a combination of an interferon and the antiviral medication ribavirin. Side effects are common and can be serious to the extent that some people are unable to continue to work.

The fact that people respond so differently to the same treatment is usually because a genetic variation in the non-responders is, via complex genetic pathways, inhibiting the effects of therapy. "The Lausanne University Hospital (CHUV) has a large cohort of Hepatitis C patients seen at the hospital over many years," said Dr. Kutalik, "so this provided the opportunity for us to do a genome-wide association study on 1362 of them to see if we could track down any differences relating to patients' failure to respond to therapy."

Genome-wide association studies look at variations across the entire genome of individuals to look for genetic associations with well-defined traits, including why some people get a particular disease and condition as well as why they might react or not to therapy for it. In this case, approximately half of the patients studied had responded successfully to therapy, giving the scientists the opportunity to compare their genomes with those from patients who had not responded.

"Using a gene-chip technology, a team of clinicians, geneticists and statisticians looked at over one million polymorphic nucleotides, the letters A, C, G and T of the DNA sequence," said Dr. Kutalik. "Our analysis revealed that a single nucleotide polymorphism, or SNP, was present in a gene called IL28B, which encodes for interferon lambda. This was significantly associated with both natural and drug-induced clearance of the hepatitis C virus from the body. This polymorphism may exert its influence by modulating the expression level of the interferon lambda gene."

Individuals who carry the protective allele (letter) at this genetic locus are twice as likely to clear the virus and, even if they do not, they will respond to therapy in a sustained manner; the scientists say. "Individuals infected with the less malignant subtype of the virus and carrying no risk allele were five times more likely to respond than those who were infected with other subtypes and who carried at least one copy of the risk allele. Based on our results we can speculate that the interferon lamda gene is key to increasing the success of therapy, as such therapy could, in theory, compensate for the effect of the polymorphism. Phase 1B trials of interferon lamda therapy in patients with hepatitis C have already shown promising results," Dr. Kutalik said.

The scientists intend to follow up their work by focusing on a better understanding of the more complex characteristics of hepatitis C, including finding the genetic variants that are responsible for hepatitis C liver fibrosis. "This disease affects up to 300 million people worldwide. It is insidious, and often individuals are not aware that they are infected until serious liver damage has taken place," said Dr. Kutalik. "Finding better treatments is vital. As well as sparing those who would not react well to current treatment from side effects, we hope that our work may provide pointers to the development of effective therapies for the future."

European Society of Human Genetics. (2010, June 13). Small genetic variant can predict response to hepatitis C treatment. ScienceDaily. Retrieved March 31, 2015 from www.sciencedaily.com/releases/2010/06/100613115149.htm

More From ScienceDaily

More Health & Medicine News

Featured Research

Mar. 31, 2015  A drug being developed to treat osteoporosis may also be useful for treating osteogenesis imperfecta or brittle bone disease, a rare but potentially debilitating bone disorder that that is present ... full story

Mar. 31, 2015  It is possible to quantify and classify the effects of different diseases on the activity of intestinal bacteria, new research demonstrates for the first time. Human intestinal flora, known as ... full story

Mar. 31, 2015  During prenatal development, the brains of most animals, including humans, develop specifically male or female characteristics. But scientists have known little about the details of how this ... full story

Mar. 31, 2015  A history of depression may put women at risk for developing diabetes during pregnancy, according to research. This study also pointed to how common depression is during pregnancy and the need for ... full story

Mar. 31, 2015  Women who are abused by their partner or ex-partner are much less likely to use contraception; this exposes them to sexually transmitted diseases and leads to more frequent unintended pregnancies and ... full story

Mar. 31, 2015  Babies receiving poor nutrition in the womb tend to be smaller at birth, which has been linked to the development of obesity and other health problems later in life. Researchers continue to discover ... full story

Mar. 31, 2015  In addition to their physical injuries, women who are victims of domestic violence are also at a greater risk of mental health problems such as depression and psychotic symptoms. "We studied the ... full story

Mar. 31, 2015  New research has scientists re-thinking how a lethal fungus grows and kills immune cells. The study hints at a new approach to therapy for Candida albicans, one of the most common causes of ... full story

Mar. 31, 2015  As the United States faces transplant waiting lists that continue to grow longer over time, there is increasing debate about the proper way to incentivize living donations. Due to organ shortages, ... full story

Featured Videos

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015)  The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports.
Video provided by Reuters

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015)  Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline.
Video provided by Washington Post

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015)  Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17
Video provided by AFP

Related Stories

May 9, 2014  Levels of interferon-stimulated genes in the liver and blood could help predict if a patient with hepatitis C will respond to conventional therapy, researchers suggest. The team analyzed liver and ... full story

Mar. 17, 2014  The risk of hepatitis C-associated serious liver disease persists in HIV patients otherwise benefiting from antiretroviral therapy (ART) to treat HIV, a study has found. It has been suggested that ... full story

Apr. 26, 2013  People born during 1945 through 1965 are five times more likely than other adults to be infected with hepatitis C. If you were born during these years, talk to your doctor about getting ... full story

Jan. 9, 2013  Scientists have discovered a gene that interferes with the clearance of hepatitis C virus infection. They also identified an inherited variant within this gene, Interferon Lambda 4 (IFNL4), that ... full story

Feb. 1, 2011  Researchers examined the role of later acquisition of hepatitis C in HIV patients in a new study. The findings suggest HIV patients should have access to ongoing screening for hepatitis ... full story

ScienceDaily features breaking news and videos about the latest discoveries in health, technology, the environment, and more -- from major news services and leading universities, scientific journals, and research organizations.